GeneDx CEO Katherine Stueland likes the potential of newborn testing, but she says her Stamford, Connecticut, company is still studying the idea. A potential challenge: Insurers would have to embrace ...
No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure TrialAchieve Reiterates Planned Cytisinicline NDA Submission in Q2 ...
Houston-based Moleculin Biotech, Inc., currently trading at $0.80 and showing a market capitalization of $2.4 million, has entered into an agreement with an investor to modify certain terms of ...
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC. Amezalpat builds momentum with both Fast Track and Orphan Drug Designations.
Individuals targeted for enrolment were contacted by email by a research ... Some novice clinical researchers directly used the data collection form without a pilot study and modified it only when ...
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle ...
AFRICA CDC’s support for MOSA, a pan-African randomized trial for the mpox study, has enabled enrolment of the first patients at Mbandaka Hospital in Equateur Province, Democratic Republic of Congo ...